A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients With Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After At Least One Line of Prior Therapy

Trial Profile

A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients With Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After At Least One Line of Prior Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Vistusertib (Primary) ; Paclitaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms STORK
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 02 Jan 2017 Planned End Date changed from 1 Aug 2016 to 1 Jan 2017.
    • 04 Mar 2016 Planned End Date changed from 1 Sep 2017 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top